The team found patients who received the combination were less likely to develop widespread disease or hormone-resistant cancer, suggesting the treatment may offer benefits beyond delaying the initial return of the disease.
The findings, published in the journal European Urology, come from an updated analysis of the phase 2 LUNAR trial, which followed men for nearly three years after their prostate cancer had returned and was detected in a limited number of sites.